Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | PMC:PMC10774651 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
GSE225919 RNA-seq of Snu-449 cells treated with Ezetimibe or control
Contributor : Yuting YINSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapienspurpose:different gene enrichment (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - December 25, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
CONCLUSION: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.PMID:38141196 | DOI:10.2174/0115701611267835231210054909 (Source: Atherosclerosis)
Source: Atherosclerosis - December 23, 2023 Category: Cardiology Authors: Debabrata Mukherjee Steven E Nissen Source Type: research
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
CONCLUSION: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.PMID:38141196 | DOI:10.2174/0115701611267835231210054909 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 23, 2023 Category: Drugs & Pharmacology Authors: Debabrata Mukherjee Steven E Nissen Source Type: research
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
CONCLUSION: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.PMID:38141196 | DOI:10.2174/0115701611267835231210054909 (Source: Atherosclerosis)
Source: Atherosclerosis - December 23, 2023 Category: Cardiology Authors: Debabrata Mukherjee Steven E Nissen Source Type: research
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
CONCLUSION: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.PMID:38141196 | DOI:10.2174/0115701611267835231210054909 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 23, 2023 Category: Drugs & Pharmacology Authors: Debabrata Mukherjee Steven E Nissen Source Type: research
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
CONCLUSION: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.PMID:38141196 | DOI:10.2174/0115701611267835231210054909 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 23, 2023 Category: Drugs & Pharmacology Authors: Debabrata Mukherjee Steven E Nissen Source Type: research
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk
CONCLUSION: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.PMID:38141196 | DOI:10.2174/0115701611267835231210054909 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 23, 2023 Category: Drugs & Pharmacology Authors: Debabrata Mukherjee Steven E Nissen Source Type: research
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
AbstractPurpose of ReviewTo discuss the history of cardiovascular outcomes trials of cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next-generation, oral, once-daily, low-dose CETP inhibitor in late-stage development for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).Recent FindingsPhase 1 and 2 trials have evaluated the safety and lipid/lipoprotein effects of obicetrapib as monotherapy, in conjunction with statins, on top of high-intensity statins (HIS), and with ezetimibe on top of HIS. In ROSE2, 10 mg obicetrapib monotherapy and combined with 10 mg ezetimibe, each...
Source: Current Atherosclerosis Reports - December 22, 2023 Category: Cardiology Source Type: research
Genes, Vol. 15, Pages 4: Ezetimibe Induces Paraptosis through Niemann & ndash;Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells
In conclusion, our study highlights the potential of Ezetimibe as an anticancer agent by triggering paraptosis in HCC cells. (Source: Genes)
Source: Genes - December 19, 2023 Category: Genetics & Stem Cells Authors: Yuting Yin Chun Wu Yufeng Zhou Meiyin Zhang Shijuan Mai Minshan Chen Hui-Yun Wang Tags: Article Source Type: research
Molecules, Vol. 28, Pages 7931: Indole Diterpene Derivatives from the Aspergillus flavus GZWMJZ-288, an Endophytic Fungus from Garcinia multiflora
Zuo
Liping Wang
A new indole diterpene, 26-dihydroxyaflavininyl acetate (1), along with five known analogs (2–6) were isolated from the liquid fermentation of Aspergillus flavus GZWMJZ-288, an endophyte from Garcinia multiflora. The structures of these compounds were identified through NMR, MS, chemical reaction, and X-ray diffraction experiments. Enzyme inhibition activity screening found that compounds 1, 4, and 6 have a good binding affinity with NPC1L1, among which compound 6 exhibited a stronger binding ability than ezetimibe at a concentration of 10 µM. Moreover, compound 5 showed in...
Source: Molecules - December 4, 2023 Category: Chemistry Authors: Dongyang Wang Xiaohong Zhuang Ying Yin Dan Wu Wenwen He Weiming Zhu Yanchao Xu Mingxing Zuo Liping Wang Tags: Article Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | PMC:PMC10695717 | DOI:10.4093/dmj.2023.0171 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research
